XMD8-87

Target: This ligand targets extracellular signal-regulated kinase 5 ERK5/MAPK7 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for extracellular signal-regulated kinase 5 ERK5/MAPK7. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings extracellular signal-regulated kinase 5 ERK5/MAPK7 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Design for Degradation: XMD8-87 can serve as a ligand module in PROTACs to recruit an E3 ligase and induce selective degradation of the target protein. By tuning linker length and attachment points, researchers can optimize ternary complex formation, ubiquitination efficiency, and degradation potency in cellular assays.

• Ternary Complex Optimization: Incorporating XMD8-87 into PROTAC architectures enables systematic evaluation of cooperative binding between the target ligand, E3 ligase binder, and the target protein. Researchers can compare PROTAC variants to identify conditions that maximize stable ternary complex formation, a key determinant of ubiquitination kinetics and sustained protein loss.

• Mechanism Studies via Ubiquitination: PROTACs built with XMD8-87 are suitable tools to dissect degradation mechanisms, including ubiquitin chain recruitment and dependence on the ubiquitin–proteasome pathway. Using proteasome inhibition, ubiquitination readouts, and time-course Western analyses, teams can quantify degradation rates and distinguish between degradation and mere inhibition.

• Target Selectivity Profiling: XMD8-87–based PROTACs can be used to map target selectivity by monitoring degradation across related proteins and signaling nodes. Proteomic profiling or focused panel assays help determine off-target degradation risk, enabling refinement of ligand engagement and PROTAC design to improve specificity while maintaining robust target turnover.

Structure: The structure of XMD8-87 is characterized by primary or secondary amine/basic nitrogen centers. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.